Document center
A hand picked selection of interesting presentations and info
European Charter for Access to Research Infrastructures Principles and Guidelines for Access and Related Services
The European Charter for Access to Research Infrastructures sets out non-regulatory principles and guidelines to be used as a reference when defining Access policies for Research Infrastructures and related services. While not having any legally binding nature, Research Infrastructures are encouraged to use this Charter as a reference when updating existing or defining new Access policies. In addition, the funding organisations of Research Infrastructures are invited to promote this Charter’s provisions. The update of the Charter published in 2015 is part of the ERA Policy Agenda 2022- 2024. (from the abstract of the study)
myOVERVIEW
-
sign up for personalised information
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Testimonial
Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
